Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 12/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17833754 | 0.85 | GHSR (0.42) | NR1H2GHSRESR2 | |
| SCHEMBL17833756 | 0.83 | GHSR (0.39) | MEN1KMT2ANR1H2GHSR | |
| SCHEMBL12295500 | 0.81 | GHSR (0.39) | MEN1KMT2ALMNANR1H2CYP3A4 | |
| SCHEMBL12295499 | 0.81 | GHSR (0.39) | MEN1KMT2ALMNANR1H2CYP3A4 | |
| SCHEMBL24325412 | 0.78 | MEN1 (0.44) | MEN1KMT2ANR1H2GHSRESR2 | |
| SCHEMBL16203017 | 0.78 | GHSR (0.49) | MEN1KMT2ANR1H2GHSRESR2 | |
| SCHEMBL17833752 | 0.78 | GHSR (0.41) | MEN1KMT2ALMNAGHSR | |
| SCHEMBL17833757 | 0.77 | ALDH1A1 (0.42) | MEN1KMT2ALMNA | |
| SCHEMBL17833751 | 0.77 | GHSR (0.36) | MEN1KMT2ALMNANR1H2GHSR | |
| SCHEMBL18066403 | 0.77 | MEN1 (0.50) | MEN1KMT2ANR1H2GHSRMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-28 | — | — | US | disclosed |
| US-9518022-B2 | Anti-HIV compounds | PROSETTA ANTIVIRAL INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160168100-A1 | ANTI-HIV COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168100-A1 | ANTI-HIV COMPOUNDS | MAVS, SARS1, NFATC1 | MEN1 2432/4885KMT2A 1269/4885LMNA 2556/4885 |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | MEN1 3715/4885KMT2A 780/4885LMNA 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.